01-05-2020 | Oncology | News | Article
Larotrectinib response best with NTRK fusion mutations
Solid tumor patients with NTRK fusion mutations experience “robust and durable responses” to treatment with larotrectinib, but those with other types of NTRK alterations derive “limited benefit” from the selective TRK inhibitor, investigators say.
10-10-2019 | Oncology | News | Article
PROfound paves the way for precision medicine in mCRPC
Treatment with the PARP inhibitor olaparib improves the outcomes of men with metastatic castration-resistant prostate cancer harboring deleterious mutations in homologous recombination repair genes, show trial results.
DNA_blue/© ClaudioVentrella / Getty Images / iStock, Pipette_rack with samples/© science photo / Fotoli, DNA mutation/© madgooch / stock.adobe.com